The Role of Nutrition in Psychedelics Clinical Trials: Key Considerations and Recommendations for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
Agnieszka Mechlińska, Aleksander Kwaśny, Michał Pastuszak, Wiesław Jerzy Cubała
Nutritional Psychiatry September 1, 2026 DOI: 10.1016/j.nupsyc.2026.100036 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative review Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT DMT |
| Key findings | Proposes that nutritional factors may plausibly affect the pharmacokinetics, pharmacodynamics, efficacy, or safety of 5-MeO-DMT, based on its serotonergic receptor profile and indirect evidence, though direct clinical evidence is lacking. Argues that standardized nutritional assessments in future trials could clarify interindividual variability. |
Abstract
ABSTRACT Psychedelic compounds exhibit diverse pharmacological and clinical effects, underscoring the need for further research and the development of clear guidelines to support their safe and effective clinical use. Growing interest in psychedelics has also increased attention toward the relationship between nutrition, dietary habits, and psychiatric disorders. This narrative review presents the hypothesis that nutritional status, dietary patterns, body composition, gut microbiota, and selected food–drug interactions may influence the pharmacokinetics, pharmacodynamics, efficacy, or safety of 5-MeO-DMT. This hypothesis is based on the pharmacological properties of 5-MeO-DMT, current knowledge of serotonergic signaling, and indirect evidence from nutritional psychiatry, psychopharmacology, and preclinical research. Direct clinical evidence supporting these interactions is currently unavailable. 5-MeO-DMT exhibits its highest affinity for the 5-HT1A receptor while also interacting with 5-HT2A receptors, providing a biological rationale for investigating potential interactions between nutrition and psychedelic treatment. Rather than proposing established clinical recommendations, this review identifies biologically plausible mechanisms, summarizes the available indirect evidence, and highlights key knowledge gaps that warrant prospective investigation. We propose that incorporating standardized nutritional assessments into future clinical trials may improve the interpretation of study outcomes and help determine whether nutritional factors contribute to interindividual variability in the efficacy or safety of 5-MeO-DMT.
Comparable studies
Other narrative reviews on 5-MeO-DMT, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Neuropharmacology of N,N-dimethyltryptamine | 2016 | Review | |
| N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Humans and animals (general) | 2018 | Review | |
| Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Humans (pharmacokinetics) | 2010 | Review | |
| Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT) | 2018 | Review | |
| A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. | 2013 | Review |
Citations in the library
Cites 34
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Neuropsychopharmacology February 25, 2022
and 29 more in the library